for people ages 18-90 (full criteria)
at San Francisco, California and other locations
study started
completion around



The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

Official Title

ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study


Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass, Kidney Diseases, Chronic Renal Insufficiency, Heart Diseases, Ravulizumab


You can join if…

Open to people ages 18-90

  • Participant weighs ≥ 30 kg
  • Planned non-emergent sternotomy with CPB procedure for the following surgeries:
  • Multi-vessel CABG
  • Valve replacement or repair; ascending aorta surgery permitted if combined with aortic valve replacement/repair
  • Combined CABG and valve surgery; inclusion of single-vessel CABG when combined with valve replacement/repair is permitted
  • Known CKD for at least 90 days (CKD Stage 3A, 3B, or 4)

You CAN'T join if...

  • Emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the Investigator.
  • Single-vessel CABG without valve surgery is planned.
  • Off-pump surgery is planned (eg, surgery without CPB).
  • Recipient of a solid organ or bone marrow transplantation.
  • Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization.
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.
  • History of unexplained, recurrent infection.
  • Any use of KRT or presence of AKI within 30 days of randomization
  • Use of any complement inhibitors, or plasmapheresis or plasma exchange within the year prior to Screening, or planned use during the course of the study.
  • Participant is not willing to be vaccinated against N meningitidis or is unwilling to receive prophylactic treatment with appropriate antibiotics, if needed
  • History of or unresolved N meningitidis infection.


  • Research Site accepting new patients
    San Francisco California 94143 United States
  • Research Site accepting new patients
    San Francisco California 94121 United States
  • Research Site accepting new patients
    Stanford California 94305 United States


accepting new patients
Start Date
Completion Date
Alexion Pharmaceuticals, Inc.
Phase 3 research study
Study Type
Expecting 736 study participants
Last Updated